Clinical Trial Update: Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 trial evaluating the JAK inhibitor tofacitinib for cutaneous lupus erythematosus and systemic lupus erythematosus in young adults; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Cutaneous Lupus, Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-07-30